Little Green Pharma Ltd has released a press release.
Psilocybin and MDMA down-scheduled
Filed with ASX ·
6ix hasn’t read this filing yet.
Little Green Pharma Ltd. on 6ix
Earlier from Little Green Pharma
- Share Purchase Plan offer extended to 16 January 2023
- Second exclusive supply agreement with Cannamedical
- Ethics approval for CBD Phase III clinical trial
- LGP significantly expands flower portfolio
- Prospectus
Later from Little Green Pharma
- Ethics approval granted for psilocybin clinical trial
- Reset Mind Sciences and HIF enter Strategic Alliance
- Trading Halt
- Successful completion of $5 million placement
- First shipment to Ilios Sante in Germany
Follow Little Green Pharma into a list and get an email when it puts out news.
Follow Little Green Pharma